Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group

被引：481

作者：

Cavo, Michele ^{[1
]}

Terpos, Evangelos ^{[2
]}

Nanni, Cristina ^{[3
]}

Moreau, Philippe ^{[4
]}

Lentzsch, Suzanne ^{[5
]}

Zweegman, Sonja ^{[6
]}

Hillengass, Jens ^{[7
]}

Engelhardt, Monika ^{[8
]}

Usmani, Saad Z. ^{[9
]}

Vesole, David H. ^{[10
]}

San-Miguel, Jesus ^{[11
]}

Kumar, Shaji K. ^{[12
]}

Richardson, Paul G. ^{[13
]}

Mikhael, Joseph R. ^{[14
]}

da Costa, Fernando Leal ^{[15
]}

Dimopoulos, Meletios-Athanassios ^{[16
]}

Zingaretti, Chiara ^{[17
]}

Abildgaard, Niels ^{[18
]}

Goldschmidt, Hartmut ^{[7
]}

Orlowski, Robert Z. ^{[19
]}

Chng, Wee Joo ^{[20
]}

Einsele, Hermann ^{[21
]}

Lonial, Sagar ^{[22
]}

Barlogie, Bart ^{[23
]}

Anderson, Kenneth C. ^{[13
]}

Rajkumar, S. Vincent ^{[12
]}

Durie, Brian G. M. ^{[24
]}

Zamagni, Elena ^{[1
]}

机构：

[1] Univ Bologna, Sch Med, Seragnoli Inst Hematol, Bologna, Italy

[2] Univ Athens, Sch Med, Dept Clin Therapeut, Athens, Greece

[3] Azienda Osped Univ Bologna, Nucl Med, Bologna, Italy

[4] Univ Hosp Nantes, Dept Haematol, Nantes, France

[5] Columbia Univ, Med Ctr, New York, NY USA

[6] Vrije Univ Amsterdam, Med Ctr, Dept Hematol, Amsterdam, Netherlands

[7] Univ Heidelberg Hosp, Dept Internal Med 5, Heidelberg, Germany

[8] Univ Freiburg, Fac Med, Dept Med Hematol Oncol & Stem Cell Transplantat, Med Ctr, Freiburg, Germany

[9] Carolinas HealthCare Syst, Levine Canc Inst, Charlotte, NC USA

[10] Hackensack UMC, John Theurer Canc Ctr, Hackensack, NJ USA

[11] Univ Navarra Clin, CIMA, IDISNA, Pamplona, Spain

[12] Mayo Clin, Dept Med, Div Hematol, Rochester, MN USA

[13] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA

[14] Mayo Clin, Div Hematol & Oncol, Phoenix, AZ USA

[15] Inst Portugues Oncol Francisco Gentil, Dept Hematol, Myeloma Clin, Lisbon, Portugal

[16] Univ Athens, Sch Med, Dept Clin Therapeut, Athens, Greece

[17] IRST IRCCS, Biostat & Clin Trial Unit, Meldola, Italy

[18] Odense Univ Hosp, Dept Hematol, Odense, Denmark

[19] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[20] Natl Univ Hlth Syst, Natl Univ Canc Inst, Singapore, Singapore

[21] Univ Hosp Wurzburg, Dept Internal Med 2, Wurzburg, Germany

[22] Emory Univ, Dept Hematol & Med Oncol, Winship Canc Inst, Atlanta, GA 30322 USA

[23] Mt Sinai Canc Inst, Tisch Canc Inst, Multiple Myeloma Program, New York, NY USA

[24] Cedars Sinai Comprehens Canc Ctr, Los Angeles, CA USA

来源：

LANCET ONCOLOGY | 2017年 / 18卷 / 04期

关键词：

POSITRON-EMISSION-TOMOGRAPHY; WHOLE-BODY MRI; FDG-PET/CT; SOLITARY PLASMACYTOMA; COMPUTED-TOMOGRAPHY; IMAGING TECHNIQUES; BONE-DISEASE; CLINICAL-PARAMETERS; PROGNOSTIC-FACTORS; FOLLOW-UP;

D O I：

10.1016/S1470-2045(17)30189-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

The International Myeloma Working Group consensus aimed to provide recommendations for the optimal use of (18)fluorodeoxyglucose (F-18-FDG) PET/CT in patients with multiple myeloma and other plasma cell disorders, including smouldering multiple myeloma and solitary plasmacytoma. F-18-FDG PET/CT can be considered a valuable tool for the work-up of patients with both newly diagnosed and relapsed or refractory multiple myeloma because it assesses bone damage with relatively high sensitivity and specificity, and detects extramedullary sites of proliferating clonal plasma cells while providing important prognostic information. The use of F-18-FDG PET/CT is mandatory to confirm a suspected diagnosis of solitary plasmacytoma, provided that whole-body MRI is unable to be performed, and to distinguish between smouldering and active multiple myeloma, if whole-body X-ray (WBXR) is negative and whole-body MRI is unavailable. Based on the ability of F-18-FDG PET/CT to distinguish between metabolically active and inactive disease, this technique is now the preferred functional imaging modality to evaluate and to monitor the effect of therapy on myeloma-cell metabolism. Changes in FDG avidity can provide an earlier evaluation of response to therapy compared to MRI scans, and can predict outcomes, particularly for patients who are eligible to receive autologous stem-cell transplantation. F-18-FDG PET/CT can be coupled with sensitive bone marrow-based techniques to detect minimal residual disease (MRD) inside and outside the bone marrow, helping to identify those patients who are defined as having imaging MRD negativity.

引用

页码：E206 / E217

页数：12

共 76 条

[1]

Agool A, 2006, J NUCL MED, V47, P1592

[2]

Is there any complimentary role of F-18 NaF PET/CT in detecting of osseous involvement of multiple myeloma? A comparative study for F-18 FDG PET/CT and F-18 FDG NaF PET/CT [J].